This session explores the critical roles of metabolic hormones, such as insulin, glucagon, ghrelin, or leptin, in regulating key physiological processes across body systems. We will hold a deeper understanding of how these hormones not only influence energy balance and glucose metabolism but also impact broader physiological systems, including cardiovascular, brain, liver and beyond.

In this session, we will delve into the interplay between nutrition and metabolic hormone regulation. From macronutrient composition to bioactive food components, diet plays a pivotal role in modulating metabolic hormones. This session will explore how dietary patterns and nutrients influence metabolic signaling pathways, appetite control, and energy homeostasis to gain deeper insights into how nutrition can be leveraged to complement hormone-based therapies.

Deep knowledge experts on the science of metabolic hormones and their impact on various body systems will present their research. In addition to gaining a deeper understanding of the science, we will discuss how understanding these impacts can provide opportunities in the food and health industries.

Understanding the metabolic impacts of GLP-1 and similar drugs on the brain is essential—especially for the food and health industries—for several reasons that go far beyond simple appetite suppression. Consumers may fundamentally think and feel differently about food. This challenges traditional marketing, sensory design, and product positioning that rely on cravings, nostalgia, or indulgence cues. Changes in the brain may remain altered long after someone stops the drug. Understanding brain-based metabolic changes is crucial not only for targeting consumers effectively, but for reimagining what food means to society.

People on GLP-1s eat less, drink less alcohol, and make fewer impulse purchases. This is generally bad news for the food industry. How are food companies evolving and creating new opportunities? How can we all evolve together to ensure a healthier population, a reduced incidence of obesity and disease, as well as successful market valuations? Hear some examples from forward-thinking, innovative companies on how they are, or might leverage the opportunities inherent in this evolving marketplace.

As GLP-1 therapies redefine the landscape of metabolic health, AI is emerging as a critical tool for navigating this new frontier. This session will examine the practical role of AI in advancing precision nutrition, particularly in the context of metabolic hormone therapies such as GLP-1 receptor agonists. We will discuss how AI-driven models can be leveraged to analyze complex biological, dietary, and clinical data to better understand individual variability in metabolic responses. Attendees will gain insight into current research and applications of AI that support data-informed decision-making in nutrition science, with a focus on opportunities and challenges in integrating AI into personalized health and food system solutions.

As GLP-1 therapies alter appetite, metabolism, and body composition, the role of protein in nutritional strategies is gaining renewed attention. In this session, explore how precision approaches to protein nutrition can support muscle maintenance, metabolic health, and satiety in individuals using GLP-1-based medications. Drawing on insights from biotechnology and nutritional science, Schmidt will discuss opportunities for developing tailored protein solutions both in formulation and delivery—that align with the physiological changes associated with GLP-1 use. This session will highlight practical considerations and innovation pathways for aligning protein nutrition with the needs of a changing metabolic health market.

This interdisciplinary panel will bring together leading scientists and industry experts to discuss the evolving role of precision nutrition in the context of GLP-1 therapies and metabolic health. Panelists will share insights from their respective fields—including -omic technologies, gut microbiome research, lipid metabolism and brain health, personalized nutrition, and functional ingredient development—highlighting how scientific advancements are shaping targeted dietary strategies.

As GLP-1 therapies become central to managing obesity and metabolic disease, nutrition plays a pivotal role in long-term patient success. In this session, we will share clinical insights on how patients experience and adapt to metabolic hormone interventions. This session will discuss how these therapies influence dietary patterns over time and discuss strategies to address reduced appetite, ensure adequate nutrient intake, and promote sustainable nutritional support.

Founders, investors, and R&D leaders at the forefront of nutrition and metabolic health innovation will discuss how startups are responding to the rise of GLP-1 therapies and the growing demand for personalized, functional nutrition solutions. Panelists will share perspectives on product development, clinical validation, market adoption, and the role of biotech and food tech in addressing emerging consumer needs